Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Abivax SA American Depositary Shares (ABVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ABVX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $36.62
1 Year Target Price $36.62
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.78% | Avg. Invested days 41 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 469.56M USD | Price to earnings Ratio - | 1Y Target Price 36.62 |
Price to earnings Ratio - | 1Y Target Price 36.62 | ||
Volume (30-day avg) 7 | Beta 1.51 | 52 Weeks Range 4.77 - 14.16 | Updated Date 06/30/2025 |
52 Weeks Range 4.77 - 14.16 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.45 |
Earnings Date
Report Date 2025-06-02 | When After Market | Estimate -0.76 | Actual -0.95 |
Profitability
Profit Margin - | Operating Margin (TTM) -4865.98% |
Management Effectiveness
Return on Assets (TTM) -48.6% | Return on Equity (TTM) -196.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 451525520 | Price to Sales(TTM) 44.35 |
Enterprise Value 451525520 | Price to Sales(TTM) 44.35 | ||
Enterprise Value to Revenue 157.63 | Enterprise Value to EBITDA -12.66 | Shares Outstanding 63454200 | Shares Floating 27518029 |
Shares Outstanding 63454200 | Shares Floating 27518029 | ||
Percent Insiders - | Percent Institutions 50.19 |
Analyst Ratings
Rating 3 | Target Price 36.62 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Abivax SA American Depositary Shares
Company Overview
History and Background
Abivax SA is a clinical-stage biotechnology company focused on developing novel therapies for inflammatory diseases, viral infections, and cancer. Founded in 2013, it leverages its platform to discover and develop therapeutic candidates.
Core Business Areas
- Viral Diseases: Development of therapies for chronic viral infections, including HIV.
- Inflammatory Diseases: Development of therapies for chronic inflammatory diseases, such as ulcerative colitis.
- Oncology: Development of therapies for cancer.
Leadership and Structure
The company is led by a management team with experience in biotechnology and pharmaceuticals. Its organizational structure includes departments focused on research, clinical development, and commercialization.
Top Products and Market Share
Key Offerings
- Obefazimod: An oral treatment for ulcerative colitis currently in Phase 3 clinical trials. Its market share is yet to be determined, pending approval. Competitors include Entyvio (TAK), Remicade (JNJ), Humira (ABBV).
- ABX464 (HIV): A novel molecule targeting HIV with a unique mechanism of action. Its market share is yet to be determined. Competitors include Gilead Sciences (GILD), ViiV Healthcare (GSK).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense competition, high regulatory hurdles, and significant investment in research and development.
Positioning
Abivax is positioned as an innovative biotechnology company focused on developing novel therapies for unmet medical needs. Its competitive advantage lies in its unique platform and promising clinical trial results.
Total Addressable Market (TAM)
The inflammatory bowel disease market is estimated at $20 billion. The HIV market is estimated at $25 billion. Abivax is well-positioned to capture a significant share upon successful commercialization.
Upturn SWOT Analysis
Strengths
- Novel platform with potential for multiple therapeutic applications
- Promising clinical trial results for Obefazimod
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Reliance on successful clinical trials
- High cash burn rate
- Dependence on future funding
- Limited commercial infrastructure
Opportunities
- Potential for breakthrough therapies in unmet medical needs
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition by a larger company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent expirations
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- GILD
- ABBV
- JNJ
- TAK
- GSK
Competitive Landscape
Abivax competes with established pharmaceutical companies with larger resources and established products. Abivax's advantage is its innovative platform and potential for new treatments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to its clinical-stage nature.
Future Projections: Future growth is dependent on the success of its clinical programs and commercialization efforts. Analyst estimates are generally positive based on Obefazimod's potential.
Recent Initiatives: Recent initiatives include advancing Obefazimod to Phase 3 trials and exploring new indications for its platform.
Summary
Abivax is a clinical-stage biotech with promising pipeline assets, especially Obefazimod. The company's success hinges on favorable clinical trial results and securing adequate funding. Its novel approach and experienced team position it well, but significant risks remain regarding clinical trial outcomes and competition from larger, established players.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on publicly available data and may not be entirely accurate or complete. Past performance is not indicative of future results. The user assumes full responsibility for any investment decisions made based on this information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abivax SA American Depositary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-10-20 | CEO & Director Mr. Marc M. P. de Garidel M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 69 | Website https://www.abivax.com |
Full time employees 69 | Website https://www.abivax.com | ||
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.